Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > expensive fail for roche

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jul 04, 2024 10:22am

102 Views

Post# 36117943

RE:RE:expensive fail for roche

July 04, 2024 - "Keytruda has beaten Roche’s TIGIT drug candidate at the first interim analysis of a phase 2/3 lung cancer trial, prompting the Swiss drugmaker to stop the study and consider changes to the broader program."

The company is studying tiragolumab in a broad clinical development program, which features multiple NSCLC studies as well as trials in other forms of lung, esophageal and liver cancer. Roche has reported the failure of a small cell lung cancer trial, plus the PFS miss in SKYSCRAPER-01. An esophageal trial met its primary endpoint but the use of an outdated control therapy left doubts about clinical significance.

If SKYSCRAPER-01 keeps trending in the same direction, Roche could rack up a phase 3 OS win in NSCLC in the future. But, even if that happens, the company may again face questions about the comparator. SKYSCRAPER-01 is comparing the effect of adding tiragolumab or placebo to Tecentriq. Having failed to beat Keytruda in SKYSCRAPER-06, a win against Tecentriq in the other study could come with an asterisk."

[ Even more reason for Roche/Genentech to acquire ONCY for the pelareorep drug platform for use in the treatment of multiple cancers ]

https://www.fiercebiotech.com/biotech/roche-stops-pivotal-tigit-trial-after-keytruda-lands-knockout-blow-first-attempt

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing